カテゴリー： LP Information, 世界, 医療/バイオ

世界の23価肺炎球菌ワクチン市場予測 2021年-2026年

【英語タイトル】Global 23-valent Pneumococcal Vaccine Market Growth 2021-2026

LP Informationが出版した調査資料（LPI21MY9699）・商品コード：LPI21MY9699
・発行会社（調査会社）：LP Information
・発行日：2021年5月（※2024年版があります。お問い合わせください）
・ページ数：135
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥541,680見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥812,520見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,083,360見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
LPインフォメーション社の「23価肺炎球菌ワクチンの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、単回投与バイアル、プレフィルドシリンジなど、用途別には、慢性心血管疾患、慢性肺疾患、慢性肝疾患、ヒト免疫不全ウイルス、白血病、リンパ腫、多発性骨髄腫、一般悪性腫瘍、慢性腎臓病、その他などにセグメント区分してまとめました。23価肺炎球菌ワクチンのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・23価肺炎球菌ワクチンの世界市場概要（サマリー）
・23価肺炎球菌ワクチンの企業別販売量・売上
・23価肺炎球菌ワクチンの企業別市場シェア
・23価肺炎球菌ワクチンの世界市場規模 2016年-2021年：種類別（単回投与バイアル、プレフィルドシリンジ）
・23価肺炎球菌ワクチンの世界市場規模 2016年-2021年：用途別（慢性心血管疾患、慢性肺疾患、慢性肝疾患、ヒト免疫不全ウイルス、白血病、リンパ腫、多発性骨髄腫、一般悪性腫瘍、慢性腎臓病、その他）
・23価肺炎球菌ワクチンの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど）
・23価肺炎球菌ワクチンのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）
・23価肺炎球菌ワクチンのヨーロッパ市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・23価肺炎球菌ワクチンの中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）
・23価肺炎球菌ワクチン市場の成長要因・課題・動向
・23価肺炎球菌ワクチンの世界市場予測 2021年-2026年
・23価肺炎球菌ワクチンの南北アメリカ市場予測（アメリカ、カナダ、メキシコなど）
・23価肺炎球菌ワクチンのアジア市場予測（日本、中国、韓国、インド、東南アジアなど）
・23価肺炎球菌ワクチンのヨーロッパ市場予測（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・23価肺炎球菌ワクチンの中東・アフリカ市場予測（エジプト、南アフリカ、トルコ、GCC諸国など）
・23価肺炎球菌ワクチンの世界市場予測：種類別（単回投与バイアル、プレフィルドシリンジ）
・23価肺炎球菌ワクチンの世界市場予測：用途別（慢性心血管疾患、慢性肺疾患、慢性肝疾患、ヒト免疫不全ウイルス、白血病、リンパ腫、多発性骨髄腫、一般悪性腫瘍、慢性腎臓病、その他）
・主要企業分析
【レポートの概要】

According to this latest study, the 2021 growth of 23-valent Pneumococcal Vaccine will have significant change from previous year. By the most conservative estimates of global 23-valent Pneumococcal Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the 23-valent Pneumococcal Vaccine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of 23-valent Pneumococcal Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Single Dose Vial
Pre-filled Syringe

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Chronic Cardiovascular Disease
Chronic Lung Disease
Chronic Liver Disease
People Living with Hiv
Leukemia
Lymphoma
Multiple Myeloma
General Malignancy
Chronic Kidney Disease
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Merck
Sanofipasteur
CDIBP
Kexing Bio
Changsheng Bio-Technology
Huaan Science and Technology Innovation

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global 23-valent Pneumococcal Vaccine Consumption 2016-2026
2.1.2 23-valent Pneumococcal Vaccine Consumption CAGR by Region
2.2 23-valent Pneumococcal Vaccine Segment by Type
2.2.1 Single Dose Vial
2.2.2 Pre-filled Syringe
2.3 23-valent Pneumococcal Vaccine Sales by Type
2.3.1 Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
2.3.2 Global 23-valent Pneumococcal Vaccine Revenue and Market Share by Type (2016-2021)
2.3.3 Global 23-valent Pneumococcal Vaccine Sale Price by Type (2016-2021)
2.4 23-valent Pneumococcal Vaccine Segment by Application
2.4.1 Chronic Cardiovascular Disease
2.4.2 Chronic Lung Disease
2.4.3 Chronic Liver Disease
2.4.4 People Living with Hiv
2.4.5 Leukemia
2.4.6 Lymphoma
2.4.7 Multiple Myeloma
2.4.8 General Malignancy
2.4.9 Chronic Kidney Disease
2.4.10 Other
2.5 23-valent Pneumococcal Vaccine Sales by Application
2.5.1 Global 23-valent Pneumococcal Vaccine Sale Market Share by Application (2016-2021)
2.5.2 Global 23-valent Pneumococcal Vaccine Revenue and Market Share by Application (2016-2021)
2.5.3 Global 23-valent Pneumococcal Vaccine Sale Price by Application (2016-2021)

3 Global 23-valent Pneumococcal Vaccine by Company
3.1 Global 23-valent Pneumococcal Vaccine Sales Market Share by Company
3.1.1 Global 23-valent Pneumococcal Vaccine Sales by Company (2019-2021)
3.1.2 Global 23-valent Pneumococcal Vaccine Sales Market Share by Company (2019-2021)
3.2 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Company
3.2.1 Global 23-valent Pneumococcal Vaccine Revenue by Company (2019-2021)
3.2.2 Global 23-valent Pneumococcal Vaccine Revenue Market Share by Company (2019-2021)
3.3 Global 23-valent Pneumococcal Vaccine Sale Price by Company
3.4 Global Manufacturers 23-valent Pneumococcal Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers 23-valent Pneumococcal Vaccine Product Location Distribution
3.4.2 Players 23-valent Pneumococcal Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 23-valent Pneumococcal Vaccine by Region
4.1 Global 23-valent Pneumococcal Vaccine by Region
4.1.1 Global 23-valent Pneumococcal Vaccine Sales by Region
4.1.2 Global 23-valent Pneumococcal Vaccine Revenue by Region
4.2 Americas 23-valent Pneumococcal Vaccine Sales Growth
4.3 APAC 23-valent Pneumococcal Vaccine Sales Growth
4.4 Europe 23-valent Pneumococcal Vaccine Sales Growth
4.5 Middle East & Africa 23-valent Pneumococcal Vaccine Sales Growth

5 Americas
5.1 Americas 23-valent Pneumococcal Vaccine Sales by Country
5.1.1 Americas 23-valent Pneumococcal Vaccine Sales by Country (2016-2021)
5.1.2 Americas 23-valent Pneumococcal Vaccine Revenue by Country (2016-2021)
5.2 Americas 23-valent Pneumococcal Vaccine Sales by Type
5.3 Americas 23-valent Pneumococcal Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC 23-valent Pneumococcal Vaccine Sales by Region
6.1.1 APAC 23-valent Pneumococcal Vaccine Sales by Region (2016-2021)
6.1.2 APAC 23-valent Pneumococcal Vaccine Revenue by Region (2016-2021)
6.2 APAC 23-valent Pneumococcal Vaccine Sales by Type
6.3 APAC 23-valent Pneumococcal Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe 23-valent Pneumococcal Vaccine by Country
7.1.1 Europe 23-valent Pneumococcal Vaccine Sales by Country (2016-2021)
7.1.2 Europe 23-valent Pneumococcal Vaccine Revenue by Country (2016-2021)
7.2 Europe 23-valent Pneumococcal Vaccine Sales by Type
7.3 Europe 23-valent Pneumococcal Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa 23-valent Pneumococcal Vaccine by Country
8.1.1 Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Country (2016-2021)
8.1.2 Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Country (2016-2021)
8.2 Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Type
8.3 Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 23-valent Pneumococcal Vaccine Distributors
10.3 23-valent Pneumococcal Vaccine Customer

11 Global 23-valent Pneumococcal Vaccine Market Forecast
11.1 Global 23-valent Pneumococcal Vaccine Forecast by Region
11.1.1 Global 23-valent Pneumococcal Vaccine Forecast by Regions (2021-2026)
11.2.2 Global 23-valent Pneumococcal Vaccine Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global 23-valent Pneumococcal Vaccine Forecast by Type
11.7 Global 23-valent Pneumococcal Vaccine Forecast by Application

12 Key Players Analysis
12.1 Merck
12.1.1 Merck Company Information
12.1.2 Merck 23-valent Pneumococcal Vaccine Product Offered
12.1.3 Merck 23-valent Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Merck Main Business Overview
12.1.5 Merck Latest Developments
12.2 Sanofipasteur
12.2.1 Sanofipasteur Company Information
12.2.2 Sanofipasteur 23-valent Pneumococcal Vaccine Product Offered
12.2.3 Sanofipasteur 23-valent Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Sanofipasteur Main Business Overview
12.2.5 Sanofipasteur Latest Developments
12.3 CDIBP
12.3.1 CDIBP Company Information
12.3.2 CDIBP 23-valent Pneumococcal Vaccine Product Offered
12.3.3 CDIBP 23-valent Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 CDIBP Main Business Overview
12.3.5 CDIBP Latest Developments
12.4 Kexing Bio
12.4.1 Kexing Bio Company Information
12.4.2 Kexing Bio 23-valent Pneumococcal Vaccine Product Offered
12.4.3 Kexing Bio 23-valent Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Kexing Bio Main Business Overview
12.4.5 Kexing Bio Latest Developments
12.5 Changsheng Bio-Technology
12.5.1 Changsheng Bio-Technology Company Information
12.5.2 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product Offered
12.5.3 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Changsheng Bio-Technology Main Business Overview
12.5.5 Changsheng Bio-Technology Latest Developments
12.6 Huaan Science and Technology Innovation
12.6.1 Huaan Science and Technology Innovation Company Information
12.6.2 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product Offered
12.6.3 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Huaan Science and Technology Innovation Main Business Overview
12.6.5 Huaan Science and Technology Innovation Latest Developments
…

13 Research Findings and Conclusion

List of Tables
Table 1. 23-valent Pneumococcal Vaccine Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Single Dose Vial
Table 3. Major Players of Pre-filled Syringe
Table 4. Global 23-valent Pneumococcal Vaccine Sales by Type (2016-2021) & (K Units)
Table 5. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
Table 6. Global 23-valent Pneumococcal Vaccine Revenue by Type (2016-2021) & ($ million)
Table 7. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2016-2021)
Table 8. Global 23-valent Pneumococcal Vaccine Sale Price by Type (2016-2021)
Table 9. Global 23-valent Pneumococcal Vaccine Sales by Application (2016-2021) & (K Units)
Table 10. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2016-2021)
Table 11. Global 23-valent Pneumococcal Vaccine Value by Application (2016-2021)
Table 12. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2016-2021)
Table 13. Global 23-valent Pneumococcal Vaccine Sale Price by Application (2016-2021)
Table 14. Global 23-valent Pneumococcal Vaccine Sales by Company (2019-2021) & (K Units)
Table 15. Global 23-valent Pneumococcal Vaccine Sales Market Share by Company (2019-2021)
Table 16. Global 23-valent Pneumococcal Vaccine Revenue by Company (2019-2021) ($ Millions)
Table 17. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Company (2019-2021)
Table 18. Global 23-valent Pneumococcal Vaccine Sale Price by Company (2019-2021)
Table 19. Key Manufacturers 23-valent Pneumococcal Vaccine Producing Area Distribution and Sales Area
Table 20. Players 23-valent Pneumococcal Vaccine Products Offered
Table 21. 23-valent Pneumococcal Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 22. New Products and Potential Entrants
Table 23. Mergers & Acquisitions, Expansion
Table 24. Global 23-valent Pneumococcal Vaccine Sales by Region (2016-2021) (K Units)
Table 25. Global 23-valent Pneumococcal Vaccine Sales Market Share by Region (2016-2021)
Table 26. Global 23-valent Pneumococcal Vaccine Revenue by Region (2016-2021) & ($ Millions)
Table 27. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2016-2021)
Table 28. Americas 23-valent Pneumococcal Vaccine Sales by Country (2016-2021) & (K Units)
Table 29. Americas 23-valent Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 30. Americas 23-valent Pneumococcal Vaccine Revenue by Country (2016-2021) & ($ Millions)
Table 31. Americas 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 32. Americas 23-valent Pneumococcal Vaccine Sales by Type (2016-2021) & (K Units)
Table 33. Americas 23-valent Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
Table 34. Americas 23-valent Pneumococcal Vaccine Sales by Application (2016-2021) & (K Units)
Table 35. Americas 23-valent Pneumococcal Vaccine Sales Market Share by Application (2016-2021)
Table 36. APAC 23-valent Pneumococcal Vaccine Sales by Region (2016-2021) & (K Units)
Table 37. APAC 23-valent Pneumococcal Vaccine Sales Market Share by Region (2016-2021)
Table 38. APAC 23-valent Pneumococcal Vaccine Revenue by Region (2016-2021) & ($ Millions)
Table 39. APAC 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2016-2021)
Table 40. APAC 23-valent Pneumococcal Vaccine Sales by Type (2016-2021) & (K Units)
Table 41. APAC 23-valent Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
Table 42. APAC 23-valent Pneumococcal Vaccine Sales by Application (2016-2021) & (K Units)
Table 43. APAC 23-valent Pneumococcal Vaccine Sales Market Share by Application (2016-2021)
Table 44. Europe 23-valent Pneumococcal Vaccine Sales by Country (2016-2021) & (K Units)
Table 45. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 46. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2016-2021) & ($ Millions)
Table 47. Europe 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 48. Europe 23-valent Pneumococcal Vaccine Sales by Type (2016-2021) & (K Units)
Table 49. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
Table 50. Europe 23-valent Pneumococcal Vaccine Sales by Application (2016-2021) & (K Units)
Table 51. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Application (2016-2021)
Table 52. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Country (2016-2021) & (K Units)
Table 53. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Country (2016-2021)
Table 54. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Country (2016-2021) & ($ Millions)
Table 55. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2016-2021)
Table 56. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Type (2016-2021) & (K Units)
Table 57. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Type (2016-2021)
Table 58. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Application (2016-2021) & (K Units)
Table 59. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Application (2016-2021)
Table 60. Key and Potential Regions of 23-valent Pneumococcal Vaccine
Table 61. Key Application and Potential Industries of 23-valent Pneumococcal Vaccine
Table 62. Key Challenges of 23-valent Pneumococcal Vaccine
Table 63. Key Trends of 23-valent Pneumococcal Vaccine
Table 64. 23-valent Pneumococcal Vaccine Distributors List
Table 65. 23-valent Pneumococcal Vaccine Customer List
Table 66. Global 23-valent Pneumococcal Vaccine Sales Forecast by Region (2021-2026) & (K Units)
Table 67. Global 23-valent Pneumococcal Vaccine Consumption Market Forecast by Region
Table 68. Global 23-valent Pneumococcal Vaccine Revenue Forecast by Region (2021-2026) & ($ millions)
Table 69. Global 23-valent Pneumococcal Vaccine Revenue Market Share Forecast by Region (2021-2026)
Table 70. Americas 23-valent Pneumococcal Vaccine Sales Forecast by Country (2021-2026) & (K Units)
Table 71. Americas 23-valent Pneumococcal Vaccine Revenue Forecast by Country (2021-2026) & ($ millions)
Table 72. APAC 23-valent Pneumococcal Vaccine Sales Forecast by Region (2021-2026) & (K Units)
Table 73. APAC 23-valent Pneumococcal Vaccine Revenue Forecast by Region (2021-2026) & ($ millions)
Table 74. Europe 23-valent Pneumococcal Vaccine Sales Forecast by Country (2021-2026) & (K Units)
Table 75. Europe 23-valent Pneumococcal Vaccine Revenue Forecast by Country (2021-2026) & ($ millions)
Table 76. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Forecast by Country (2021-2026) & (K Units)
Table 77. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue Forecast by Country (2021-2026) & ($ millions)
Table 78. Global 23-valent Pneumococcal Vaccine Sales Forecast by Type (2021-2026) & (K Units)
Table 79. Global 23-valent Pneumococcal Vaccine Sales Market Share Forecast by Type (2021-2026)
Table 80. Global 23-valent Pneumococcal Vaccine Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 81. Global 23-valent Pneumococcal Vaccine Revenue Market Share Forecast by Type (2021-2026)
Table 82. Global 23-valent Pneumococcal Vaccine Sales Forecast by Application (2021-2026) & (K Units)
Table 83. Global 23-valent Pneumococcal Vaccine Sales Market Share Forecast by Application (2021-2026)
Table 84. Global 23-valent Pneumococcal Vaccine Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 85. Global 23-valent Pneumococcal Vaccine Revenue Market Share Forecast by Application (2021-2026)
Table 86. Merck Basic Information, 23-valent Pneumococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 87. Merck 23-valent Pneumococcal Vaccine Product Offered
Table 88. Merck 23-valent Pneumococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 89. Merck Main Business
Table 90. Merck Latest Developments
Table 91. Sanofipasteur Basic Information, 23-valent Pneumococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 92. Sanofipasteur 23-valent Pneumococcal Vaccine Product Offered
Table 93. Sanofipasteur 23-valent Pneumococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 94. Sanofipasteur Main Business
Table 95. Sanofipasteur Latest Developments
Table 96. CDIBP Basic Information, 23-valent Pneumococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 97. CDIBP 23-valent Pneumococcal Vaccine Product Offered
Table 98. CDIBP 23-valent Pneumococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 99. CDIBP Main Business
Table 100. CDIBP Latest Developments
Table 101. Kexing Bio Basic Information, 23-valent Pneumococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 102. Kexing Bio 23-valent Pneumococcal Vaccine Product Offered
Table 103. Kexing Bio 23-valent Pneumococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 104. Kexing Bio Main Business
Table 105. Kexing Bio Latest Developments
Table 106. Changsheng Bio-Technology Basic Information, 23-valent Pneumococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 107. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product Offered
Table 108. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 109. Changsheng Bio-Technology Main Business
Table 110. Changsheng Bio-Technology Latest Developments
Table 111. Huaan Science and Technology Innovation Basic Information, 23-valent Pneumococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 112. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product Offered
Table 113. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 114. Huaan Science and Technology Innovation Main Business
Table 115. Huaan Science and Technology Innovation Latest Developments
List of Figures
Figure 1. Picture of 23-valent Pneumococcal Vaccine
Figure 2. 23-valent Pneumococcal Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global 23-valent Pneumococcal Vaccine Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global 23-valent Pneumococcal Vaccine Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. 23-valent Pneumococcal Vaccine Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Single Dose Vial
Figure 10. Product Picture of Pre-filled Syringe
Figure 11. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type in 2020
Figure 12. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2016-2021)
Figure 13. 23-valent Pneumococcal Vaccine Consumed in Chronic Cardiovascular Disease
Figure 14. Global 23-valent Pneumococcal Vaccine Market: Chronic Cardiovascular Disease (2016-2021) & (K Units)
Figure 15. 23-valent Pneumococcal Vaccine Consumed in Chronic Lung Disease
Figure 16. Global 23-valent Pneumococcal Vaccine Market: Chronic Lung Disease (2016-2021) & (K Units)
Figure 17. 23-valent Pneumococcal Vaccine Consumed in Chronic Liver Disease
Figure 18. Global 23-valent Pneumococcal Vaccine Market: Chronic Liver Disease (2016-2021) & (K Units)
Figure 19. 23-valent Pneumococcal Vaccine Consumed in People Living with Hiv
Figure 20. Global 23-valent Pneumococcal Vaccine Market: People Living with Hiv (2016-2021) & (K Units)
Figure 21. 23-valent Pneumococcal Vaccine Consumed in Leukemia
Figure 22. Global 23-valent Pneumococcal Vaccine Market: Leukemia (2016-2021) & (K Units)
Figure 23. 23-valent Pneumococcal Vaccine Consumed in Lymphoma
Figure 24. Global 23-valent Pneumococcal Vaccine Market: Lymphoma (2016-2021) & (K Units)
Figure 25. 23-valent Pneumococcal Vaccine Consumed in Multiple Myeloma
Figure 26. Global 23-valent Pneumococcal Vaccine Market: Multiple Myeloma (2016-2021) & (K Units)
Figure 27. 23-valent Pneumococcal Vaccine Consumed in General Malignancy
Figure 28. Global 23-valent Pneumococcal Vaccine Market: General Malignancy (2016-2021) & (K Units)
Figure 29. 23-valent Pneumococcal Vaccine Consumed in Chronic Kidney Disease
Figure 30. Global 23-valent Pneumococcal Vaccine Market: Chronic Kidney Disease (2016-2021) & (K Units)
Figure 31. 23-valent Pneumococcal Vaccine Consumed in Other
Figure 32. Global 23-valent Pneumococcal Vaccine Market: Other (2016-2021) & (K Units)
Figure 33. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2016-2021)
Figure 34. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application in 2020
Figure 35. 23-valent Pneumococcal Vaccine Revenue Market by Company in 2020 ($ Million)
Figure 36. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Company in 2020
Figure 37. Global 23-valent Pneumococcal Vaccine Sales Market Share by Regions (2016-2021)
Figure 38. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region in 2020
Figure 39. Americas 23-valent Pneumococcal Vaccine Sales 2016-2021 (K Units)
Figure 40. Americas 23-valent Pneumococcal Vaccine Revenue 2016-2021 ($ Millions)
Figure 41. APAC 23-valent Pneumococcal Vaccine Sales 2016-2021 (K Units)
Figure 42. APAC 23-valent Pneumococcal Vaccine Revenue 2016-2021 ($ Millions)
Figure 43. Europe 23-valent Pneumococcal Vaccine Sales 2016-2021 (K Units)
Figure 44. Europe 23-valent Pneumococcal Vaccine Revenue 2016-2021 ($ Millions)
Figure 45. Middle East & Africa 23-valent Pneumococcal Vaccine Sales 2016-2021 (K Units)
Figure 46. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue 2016-2021 ($ Millions)
Figure 47. Americas 23-valent Pneumococcal Vaccine Sales Market Share by Country in 2020
Figure 48. Americas 23-valent Pneumococcal Vaccine Revenue Market Share by Country in 2020
Figure 49. Americas 23-valent Pneumococcal Vaccine Sales Market Share by Type in 2020
Figure 50. Americas 23-valent Pneumococcal Vaccine Sales Market Share by Application in 2020
Figure 51. United States 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 52. Canada 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 53. Mexico 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 54. Brazil 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 55. APAC 23-valent Pneumococcal Vaccine Sales Market Share by Region in 2020
Figure 56. APAC 23-valent Pneumococcal Vaccine Revenue Market Share by Regions in 2020
Figure 57. APAC 23-valent Pneumococcal Vaccine Sales Market Share by Type in 2020
Figure 58. APAC 23-valent Pneumococcal Vaccine Sales Market Share by Application in 2020
Figure 59. China 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 60. Japan 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 61. Korea 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 62. Southeast Asia 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 63. India 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 64. Australia 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 65. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Country in 2020
Figure 66. Europe 23-valent Pneumococcal Vaccine Revenue Market Share by Country in 2020
Figure 67. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Type in 2020
Figure 68. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Application in 2020
Figure 69. Germany 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 70. France 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 71. UK 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 72. Italy 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 73. Russia 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 74. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Country in 2020
Figure 75. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue Market Share by Country in 2020
Figure 76. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Type in 2020
Figure 77. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Application in 2020
Figure 78. Egypt 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 79. South Africa 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 80. Israel 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 81. Turkey 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 82. GCC Country 23-valent Pneumococcal Vaccine Revenue Growth 2016-2021 ($ Millions)
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles


★調査レポート[世界の23価肺炎球菌ワクチン市場予測 2021年-2026年] (コード：LPI21MY9699)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の23価肺炎球菌ワクチン市場予測 2021年-2026年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の13価肺炎球菌多糖結合型ワクチン（PCV13）市場予測 2021年-2026年
    LPI21MY9698 / LP Information / 2021年5月 / LPインフォメーション社の「13価肺炎球菌多糖結合型ワクチン（PCV13）の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、血清型6B、7F血清型、血清型9V、14血清型、血清型18C、血清型19A、19F血清型、23F血清型、24F血清型など、用途別には、生後6週間-15ヶ月乳児、15ヶ月-5歳子供などにセグメント区分してまとめました。13価肺炎球菌多糖結合型ワクチン（PCV13）のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・13価肺炎球菌多糖結合型ワクチン（PCV13）の世界市場概要（サマリー） ・13価肺炎球菌多糖結合型ワクチン（PCV13）の企業別販売量・売上 ・13価肺炎球菌多糖結合型ワクチン（PCV13）の企業別市場シェア ・13価肺炎球菌多糖結合型ワクチン（PCV13）の世界市場規模 2016年-2021年：種類別（血清型6B、7F血清型、血清型9V、14血清型、血清型18C、血清型19A、19F血清型、23F血清型、24F血清型） ・13価肺炎球菌多糖結合型ワクチン（PCV13）の世界市場規模 2016年-2021年：用途別（生後6週間-15ヶ月乳児、15ヶ月-5歳子供） ・13価肺炎球菌多糖結合型ワクチン（PCV13）の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・13価肺炎球菌多糖結合型ワクチン（PCV13）のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) will have significant change from previous year. By the most conservative estimates of global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth...
  • 世界の7価肺炎球菌ワクチン市場 2019年
    DATA909X02781 / QYResearch / 2019年11月22日 / ※本調査レポートは、7価肺炎球菌ワクチンの世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、単回投与バイアル、充填済みシリンジに、用途別には、病院、クリニックにセグメント区分し、7価肺炎球菌ワクチンの世界市場を分析しました。 ・エグゼクティブ・サマリー ・7価肺炎球菌ワクチンの世界市場概要 ・7価肺炎球菌ワクチンの製造コスト構成分析 ・7価肺炎球菌ワクチンの開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・7価肺炎球菌ワクチンの地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・7価肺炎球菌ワクチンのセグメント分析（種類別） （単回投与バイアル、充填済みシリンジ）...The global 7-Valent Pneumococcal Vaccine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on 7-Valent Pneumococcal Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall 7-Valent Pneumococcal Vaccine market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of 7-Valent Pneumococcal Vaccine in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の10価肺炎球菌多糖ワクチン市場 2019年
    DATA909X02631 / QYResearch / 2019年11月22日 / ※本調査レポートは、10価肺炎球菌多糖ワクチンの世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、単回投与バイアル、充填済みシリンジに、用途別には、病院、クリニックにセグメント区分し、10価肺炎球菌多糖ワクチンの世界市場を分析しました。 ・エグゼクティブ・サマリー ・10価肺炎球菌多糖ワクチンの世界市場概要 ・10価肺炎球菌多糖ワクチンの製造コスト構成分析 ・10価肺炎球菌多糖ワクチンの開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・10価肺炎球菌多糖ワクチンの地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・10価肺炎球菌多糖ワクチンのセグメント分析（種類別） （単回投与バイアル、充填済みシリンジ）...The global 10-Valent Pneumococcal Polysaccharide Vaccine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on 10-Valent Pneumococcal Polysaccharide Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall 10-Valent Pneumococcal Polysaccharide Vaccine market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of 10-Valent Pneumococcal Polysaccharide Vaccine in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...
  • 世界のダニ媒介性脳炎ワクチン市場予測 2021年-2026年
    LPI21MY9672 / LP Information / 2021年5月 / LPインフォメーション社の「ダニ媒介性脳炎ワクチンの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ヨーロッパTBEウイルス、極東TBEウイルス、シベリアTBEウイルスなど、用途別には、小児用ワクチン、成人用ワクチン、旅行者用ワクチンなどにセグメント区分してまとめました。ダニ媒介性脳炎ワクチンのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ダニ媒介性脳炎ワクチンの世界市場概要（サマリー） ・ダニ媒介性脳炎ワクチンの企業別販売量・売上 ・ダニ媒介性脳炎ワクチンの企業別市場シェア ・ダニ媒介性脳炎ワクチンの世界市場規模 2016年-2021年：種類別（ヨーロッパTBEウイルス、極東TBEウイルス、シベリアTBEウイルス） ・ダニ媒介性脳炎ワクチンの世界市場規模 2016年-2021年：用途別（小児用ワクチン、成人用ワクチン、旅行者用ワクチン） ・ダニ媒介性脳炎ワクチンの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ダニ媒介性脳炎ワクチンのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Tick-borne Encephalitis Vaccine will have significant change from previous year. By the most conservative estimates of global Tick-borne Encephalitis Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Tick-borne Encephalitis Vaccine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Tick-borne Encephalitis Vaccine market by product type,...
  • 世界のBCGワクチン販売市場予測 2021年-2026年
    LPI21MY9436 / LP Information / 2021年5月 / LPインフォメーション社の「BCGワクチン販売の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、免疫BCG、治療BCGなど、用途別には、小児科、成人などにセグメント区分してまとめました。BCGワクチン販売のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・BCGワクチン販売の世界市場概要（サマリー） ・BCGワクチン販売の企業別販売量・売上 ・BCGワクチン販売の企業別市場シェア ・BCGワクチン販売の世界市場規模 2016年-2021年：種類別（免疫BCG、治療BCG） ・BCGワクチン販売の世界市場規模 2016年-2021年：用途別（小児科、成人） ・BCGワクチン販売の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・BCGワクチン販売のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of BCG Vaccine Sales will have significant change from previous year. By the most conservative estimates of global BCG Vaccine Sales market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the BCG Vaccine Sales market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of BCG Vaccine Sales market by product type,...
  • 世界のプレフィルドワクチンシリンジ市場予測 2021年-2026年
    LPI21MY9005 / LP Information / 2021年5月 / LPインフォメーション社の「プレフィルドワクチンシリンジの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、針付き、針なしなど、用途別には、病院、診療所などにセグメント区分してまとめました。プレフィルドワクチンシリンジのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・プレフィルドワクチンシリンジの世界市場概要（サマリー） ・プレフィルドワクチンシリンジの企業別販売量・売上 ・プレフィルドワクチンシリンジの企業別市場シェア ・プレフィルドワクチンシリンジの世界市場規模 2016年-2021年：種類別（針付き、針なし） ・プレフィルドワクチンシリンジの世界市場規模 2016年-2021年：用途別（病院、診療所） ・プレフィルドワクチンシリンジの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・プレフィルドワクチンシリンジのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Prefilled Vaccine Syringes will have significant change from previous year. By the most conservative estimates of global Prefilled Vaccine Syringes market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Prefilled Vaccine Syringes market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Prefilled Vaccine Syringes market by product type,...
  • 世界の脳炎ワクチン市場予測 2021年-2026年
    LPI21MY9516 / LP Information / 2021年5月 / LPインフォメーション社の「脳炎ワクチンの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、Nakayama、Beijing、P-3、SA 14-14-2など、用途別には、子供、大人などにセグメント区分してまとめました。脳炎ワクチンのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・脳炎ワクチンの世界市場概要（サマリー） ・脳炎ワクチンの企業別販売量・売上 ・脳炎ワクチンの企業別市場シェア ・脳炎ワクチンの世界市場規模 2016年-2021年：種類別（Nakayama、Beijing、P-3、SA 14-14-2） ・脳炎ワクチンの世界市場規模 2016年-2021年：用途別（子供、大人）...According to this latest study, the 2020 growth of Encephalitis Vaccine will have significant change from previous year. By the most conservative estimates of global Encephalitis Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 1127.9 million in 2019. Over the next five years the Encephalitis Vaccine market will register a 5.8% CAGR in terms of revenue, the global market size will reach US$ 1413.7 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Encephalitis Vaccine market by product type, application, key manufacturers and...
  • 世界のワクチンコールドボックス市場予測 2021年-2026年
    LPI21MY9323 / LP Information / 2021年5月 / LPインフォメーション社の「ワクチンコールドボックスの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、5リットル以下、5〜15リットル、15〜25リットル、その他など、用途別には、ワクチン、インスリン、バイオ医薬品、IVD製品、生体試料、その他などにセグメント区分してまとめました。ワクチンコールドボックスのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ワクチンコールドボックスの世界市場概要（サマリー） ・ワクチンコールドボックスの企業別販売量・売上 ・ワクチンコールドボックスの企業別市場シェア ・ワクチンコールドボックスの世界市場規模 2016年-2021年：種類別（5リットル以下、5〜15リットル、15〜25リットル、その他） ・ワクチンコールドボックスの世界市場規模 2016年-2021年：用途別（ワクチン、インスリン、バイオ医薬品、IVD製品、生体試料、その他） ・ワクチンコールドボックスの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ワクチンコールドボックスのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Vaccine Cold Boxes will have significant change from previous year. By the most conservative estimates of global Vaccine Cold Boxes market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Vaccine Cold Boxes market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Cold Boxes market by product type,...
  • 世界の新型コロナウイルスワクチン用ガラス瓶市場予測 2021年-2026年
    LPI21MY9389 / LP Information / 2021年5月 / LPインフォメーション社の「新型コロナウイルスワクチン用ガラス瓶の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、中ホウ酸塩ホウケイ酸ガラス、低ホウ酸塩ホウケイ酸ガラスなど、用途別には、ワクチン製造、ワクチン研究などにセグメント区分してまとめました。新型コロナウイルスワクチン用ガラス瓶のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・新型コロナウイルスワクチン用ガラス瓶の世界市場概要（サマリー） ・新型コロナウイルスワクチン用ガラス瓶の企業別販売量・売上 ・新型コロナウイルスワクチン用ガラス瓶の企業別市場シェア ・新型コロナウイルスワクチン用ガラス瓶の世界市場規模 2016年-2021年：種類別（中ホウ酸塩ホウケイ酸ガラス、低ホウ酸塩ホウケイ酸ガラス） ・新型コロナウイルスワクチン用ガラス瓶の世界市場規模 2016年-2021年：用途別（ワクチン製造、ワクチン研究） ・新型コロナウイルスワクチン用ガラス瓶の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・新型コロナウイルスワクチン用ガラス瓶のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Vials for COVID-19 Vaccine will have significant change from previous year. By the most conservative estimates of global Vials for COVID-19 Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Vials for COVID-19 Vaccine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Vials for COVID-19 Vaccine...
  • 世界の樹状細胞がんワクチン市場予測 2021年-2026年
    LPI21MY9503 / LP Information / 2021年5月 / LPインフォメーション社の「樹状細胞がんワクチンの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、クレアVax、シプリューセル-T（プロベンジ）、その他など、用途別には、小児、成人などにセグメント区分してまとめました。樹状細胞がんワクチンのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・樹状細胞がんワクチンの世界市場概要（サマリー） ・樹状細胞がんワクチンの企業別販売量・売上 ・樹状細胞がんワクチンの企業別市場シェア ・樹状細胞がんワクチンの世界市場規模 2016年-2021年：種類別（クレアVax、シプリューセル-T（プロベンジ）、その他） ・樹状細胞がんワクチンの世界市場規模 2016年-2021年：用途別（小児、成人） ・樹状細胞がんワクチンの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・樹状細胞がんワクチンのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Dendritic Cell Cancer Vaccine will have significant change from previous year. By the most conservative estimates of global Dendritic Cell Cancer Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Dendritic Cell Cancer Vaccine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Dendritic Cell Cancer Vaccine...

    • ◆H&Iグローバルリサーチのお客様（例）◆